Answers are grounded in this paper and cite their sources.
T cells are key players in immune-mediated rheumatoid arthritis (RA). We previously reported that interleukin (IL)-22 + CD4 + T helper (IL-22 + Th) cells and IL-22 critically control the pathogenesis of RA. Here we monitored circulating levels of different IL-22 + Th cell subsets and measured plasma levels of IL-22, IL-17, and interferon (IFN)-γ in 60 patients with active RA following 12-week combination methotrexate (MTX) and leflunomide (LEF) therapy (MTX+LEF) and 20 healthy individuals. We found the frequencies of circulating IFN-γ − IL-17 − IL-22 + (Th22), IFN-γ − IL-17 + (total Th17), IFN-γ + IL-17 − IL-22 + (IL-22 + Th1) cells, and IFN-γ − IL-17 + IL-22 + (IL-22 + Th17) cells, as well as the plasma levels of IL-22, IL-17 and IFN-γ to be significantly reduced in RA patients that responded to treatment, but not in non-responders. Reductions in plasma IL-22 level significantly correlated with percentage of circulating Th22 cells and the decrease of plasma IL-22 level correlated with the reduction of DAS28 in responders. Our data suggests that circulating Th22 cells and plasma IL-22 level play a detrimental role in RA. The combination MTX+LEF therapy, by targeting Th22 cells and reducing IL-22 level, relieves the immune defects and ameliorates symptoms of RA. This study provides novel mechanistic understanding of the pathogenesis of RA, which may promote a design of better therapies for RA.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: